401 related articles for article (PubMed ID: 27440064)
1. Antidrug Antibody Formation in Oncology: Clinical Relevance and Challenges.
van Brummelen EM; Ros W; Wolbink G; Beijnen JH; Schellens JH
Oncologist; 2016 Oct; 21(10):1260-1268. PubMed ID: 27440064
[TBL] [Abstract][Full Text] [Related]
2. Reporting, Visualization, and Modeling of Immunogenicity Data to Assess Its Impact on Pharmacokinetics, Efficacy, and Safety of Monoclonal Antibodies.
Passey C; Suryawanshi S; Sanghavi K; Gupta M
AAPS J; 2018 Feb; 20(2):35. PubMed ID: 29484520
[TBL] [Abstract][Full Text] [Related]
3. Subset analysis of patients experiencing clinical events of a potentially immunogenic nature in the pivotal clinical trials of tocilizumab for rheumatoid arthritis: Evaluation of an antidrug antibody ELISA using clinical adverse event-driven immunogenicity testing.
Stubenrauch K; Wessels U; Birnboeck H; Ramirez F; Jahreis A; Schleypen J
Clin Ther; 2010 Aug; 32(9):1597-609. PubMed ID: 20974317
[TBL] [Abstract][Full Text] [Related]
4. Assessment of the effects of immunogenicity on the pharmacokinetics, efficacy and safety of tildrakizumab.
Kimball AB; Kerbusch T; van Aarle F; Kulkarni P; Li Q; Blauvelt A; Papp KA; Reich K; Montgomery D
Br J Dermatol; 2020 Jan; 182(1):180-189. PubMed ID: 30916381
[TBL] [Abstract][Full Text] [Related]
5. Antidrug Antibodies Against Immune Checkpoint Blockers: Impairment of Drug Efficacy or Indication of Immune Activation?
Enrico D; Paci A; Chaput N; Karamouza E; Besse B
Clin Cancer Res; 2020 Feb; 26(4):787-792. PubMed ID: 31757876
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity of Golimumab and its Clinical Relevance in Patients With Ulcerative Colitis.
Adedokun OJ; Gunn GR; Leu JH; Gargano C; Xu Z; Sandborn WJ; Rutgeerts P; Shankar G
Inflamm Bowel Dis; 2019 Aug; 25(9):1532-1540. PubMed ID: 30753466
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity of Therapeutic Antibodies: Monitoring Antidrug Antibodies in a Clinical Context.
Bloem K; Hernández-Breijo B; Martínez-Feito A; Rispens T
Ther Drug Monit; 2017 Aug; 39(4):327-332. PubMed ID: 28463887
[TBL] [Abstract][Full Text] [Related]
8. Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits minimal immunogenicity in patients with moderate-to-severe plaque psoriasis.
Reich K; Blauvelt A; Armstrong A; Langley RG; Fox T; Huang J; Papavassilis C; Liang E; Lloyd P; Bruin G
Br J Dermatol; 2017 Mar; 176(3):752-758. PubMed ID: 27518376
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Immunogenicity of Nivolumab Monotherapy and Its Clinical Relevance in Patients With Metastatic Solid Tumors.
Agrawal S; Statkevich P; Bajaj G; Feng Y; Saeger S; Desai DD; Park JS; Waxman IM; Roy A; Gupta M
J Clin Pharmacol; 2017 Mar; 57(3):394-400. PubMed ID: 27557786
[TBL] [Abstract][Full Text] [Related]
10. Preclinical Observations of Systemic and Ocular Antidrug Antibody Response to Intravitreally Administered Drugs.
Wessels U; Zadak M; Weidmann AM; Stuchly T; Stubenrauch KG
AAPS J; 2022 Nov; 25(1):2. PubMed ID: 36414857
[TBL] [Abstract][Full Text] [Related]
11. The Molecular Mechanisms That Underlie the Immune Biology of Anti-drug Antibody Formation Following Treatment With Monoclonal Antibodies.
Vaisman-Mentesh A; Gutierrez-Gonzalez M; DeKosky BJ; Wine Y
Front Immunol; 2020; 11():1951. PubMed ID: 33013848
[TBL] [Abstract][Full Text] [Related]
12. Detection of antibodies to anti-TNF agents in psoriatic patients: a preliminary study.
Cozzani E; Burlando M; Parodi A
G Ital Dermatol Venereol; 2013 Apr; 148(2):171-4. PubMed ID: 23588142
[TBL] [Abstract][Full Text] [Related]
13. The Immunogenicity of Biologic Therapies.
Garcês S; Demengeot J
Curr Probl Dermatol; 2018; 53():37-48. PubMed ID: 29131036
[TBL] [Abstract][Full Text] [Related]
14. Epitope characterization of the ADA response directed against a targeted immunocytokine.
Stubenrauch K; Künzel C; Vogel R; Tuerck D; Schick E; Heinrich J
J Pharm Biomed Anal; 2015 Oct; 114():296-304. PubMed ID: 26093509
[TBL] [Abstract][Full Text] [Related]
15. Characterization and root cause analysis of immunogenicity to pasotuxizumab (AMG 212), a prostate-specific membrane antigen-targeting bispecific T-cell engager therapy.
Penny HL; Hainline K; Theoharis N; Wu B; Brandl C; Webhofer C; McComb M; Wittemer-Rump S; Koca G; Stienen S; Bargou RC; Hummel HD; Loidl W; Grüllich C; Eggert T; Tran B; Mytych DT
Front Immunol; 2023; 14():1261070. PubMed ID: 37942314
[TBL] [Abstract][Full Text] [Related]
16. Drug monitoring of biologics in inflammatory bowel disease.
Eser A; Primas C; Reinisch W
Curr Opin Gastroenterol; 2013 Jul; 29(4):391-6. PubMed ID: 23703367
[TBL] [Abstract][Full Text] [Related]
17. Evaluating and Reporting the Immunogenicity Impacts for Biological Products--a Clinical Pharmacology Perspective.
Wang YM; Wang J; Hon YY; Zhou L; Fang L; Ahn HY
AAPS J; 2016 Mar; 18(2):395-403. PubMed ID: 26721560
[TBL] [Abstract][Full Text] [Related]
18. Hypersensitivity reactions to biologics used in rheumatology.
Matucci A; Nencini F; Maggi E; Vultaggio A
Expert Rev Clin Immunol; 2019 Dec; 15(12):1263-1271. PubMed ID: 31639316
[No Abstract] [Full Text] [Related]
19. Novel drug and soluble target tolerant antidrug antibody assay for therapeutic antibodies bearing the P329G mutation.
Wessels U; Schick E; Ritter M; Kowalewsky F; Heinrich J; Stubenrauch K
Bioanalysis; 2017 Jun; 9(11):849-859. PubMed ID: 28517957
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity of TNF-Inhibitors.
Atiqi S; Hooijberg F; Loeff FC; Rispens T; Wolbink GJ
Front Immunol; 2020; 11():312. PubMed ID: 32174918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
